Search

Your search keyword '"Canonica, G.W."' showing total 455 results
Start Over Author "Canonica, G.W."
455 results on '"Canonica, G.W."'

1. Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app

Author

Bousquet, J., Sousa-Pinto, B., Anto, J.M., Amaral, R., Brussino, L., Canonica, G.W., Cruz, A.A., Gemicioglu, B., Haahtela, T., Kupczyk, M., Kvedariene, V., Larenas-Linnemann, D.E., Louis, R., Pham-Thi, N., Puggioni, F., Regateiro, F.S., Romantowski, J., Sastre, J., Scichilone, N., Taborda-Barata, L., Ventura, M.T., Agache, I., Bedbrook, A., Bergmann, K.C., Bosnic-Anticevich, S., Bonini, M., Boulet, L.-P., Brusselle, G., Buhl, R., Cecchi, L., Charpin, D., Chaves-Loureiro, C., Czarlewski, W., de Blay, F., Devillier, P., Joos, G., Jutel, M., Klimek, L., Kuna, P., Laune, D., Pech, J.L., Makela, M., Morais-Almeida, M., Nadif, R., Niedoszytko, M., Ohta, K., Papadopoulos, N.G., Papi, A., Yeverino, D.R., Roche, N., Sá-Sousa, A., Samolinski, B., Shamji, M.H., Sheikh, A., Suppli Ulrik, C., Usmani, O.S., Valiulis, A., Vandenplas, O., Yorgancioglu, A., Zuberbier, T., and Fonseca, J.A.

Published
2023
Full Text
View/download PDF

2. Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study

Author

Sousa-Pinto, B., Louis, R., Anto, J.M., Amaral, R., Sá-Sousa, A., Czarlewski, W., Brussino, L., Canonica, G.W., Chaves Loureiro, C., Cruz, A.A., Gemicioglu, B., Haahtela, T., Kupczyk, M., Kvedariene, V., Larenas-Linnemann, D.E., Okamoto, Y., Ollert, M., Pfaar, O., Pham-Thi, N., Puggioni, F., Regateiro, F.S., Romantowski, J., Sastre, J., Scichilone, N., Taborda-Barata, L., Ventura, M.T., Agache, I., Bedbrook, A., Becker, S., Bergmann, K.C., Bosnic-Anticevich, S., Bonini, M., Boulet, L.-P., Brusselle, G., Buhl, R., Cecchi, L., Charpin, D., de Blay, F., Del Giacco, S., Ivancevich, J.C., Jutel, M., Klimek, L., Kraxner, H., Kuna, P., Laune, D., Makela, M., Morais-Almeida, M., Nadif, R., Niedoszytko, M., Papadopoulos, N.G., Papi, A., Patella, V., Pétré, B., Rivero Yeverino, D., Robalo Cordeiro, C., Roche, N., Rouadi, P.W., Samolinski, B., Savouré, M., Shamji, M.H., Sheikh, A., Suppli Ulrik, C., Usmani, O.S., Valiulis, A., Yorgancioglu, A., Zuberbier, T., Fonseca, J.A., Costa, E.M., and Bousquet, J.

Published
2023
Full Text
View/download PDF

3. International Variation in Exacerbation Rates in Patients With Severe Asthma

Author

Yadav, C.P., primary, Lee, T.Y., additional, Price, D.B., additional, Roy, R., additional, Mien, L.L.H., additional, Wang, E., additional, Wechsler, M.E., additional, Jackson, D.J., additional, Busby, J., additional, Heaney, L.G., additional, Pfeffer, P.E., additional, Mahboub, B., additional, Perng, D.-W., additional, Cosio, B.G., additional, Perez-De-Llano, L., additional, AL Lohebi, R., additional, Linnemann, D.L., additional, Al-Ahmad, M., additional, Rhee, C.K., additional, Iwanaga, T., additional, Heffler, E., additional, Canonica, G.W., additional, Costello, R.W., additional, Papadopoulos, N., additional, Papaioannou, A., additional, Porsbjerg, C.M., additional, Torres-Duque, C.A., additional, Christoff, G.C., additional, Popov, T.A., additional, Hew, M., additional, Peters, M., additional, Gibson, P.G., additional, Maspero, J., additional, Bergeron, C., additional, Cerda, S., additional, Contreras, M.A., additional, Chen, W., additional, and Sadatsafavi, M., additional

Published
2024
Full Text
View/download PDF

4. Unveiling the Real-World Causal Interaction of Essential Risk Factors in Severe Asthma Exacerbation: A Bayesian Network Analysis

Author

Yadav, C.P., primary, Chakraborty, A., additional, Price, D., additional, Beasley, R., additional, Sadatsafavi, M., additional, Janson, C., additional, Siyue, M.K., additional, Wang, E., additional, Wechsler, M.E., additional, Jackson, D.J., additional, Busby, J., additional, Heaney, L.G., additional, Pfeffer, P.E., additional, Mahboub, B., additional, Perng, D.-W., additional, Cosio, B.G., additional, Perez-De-Llano, L., additional, AL Lohebi, R., additional, Linnemann, D.L., additional, Al-Ahmad, M., additional, Rhee, C.K., additional, Iwanaga, T., additional, Heffler, E., additional, Canonica, G.W., additional, Costello, R.W., additional, Papadopoulos, N., additional, Papaioannou, A., additional, Porsbjerg, C., additional, Torres-Duque, C.A., additional, Christoff, G.C., additional, Popov, T.A., additional, Hew, M., additional, Peters, M., additional, Gibson, P.G., additional, Maspero, J.F., additional, Bergeron, C., additional, Cerda, S., additional, Contreras, M.A., additional, and Chen, W., additional

Published
2024
Full Text
View/download PDF

5. Chronic rhinosinusitis with nasal polyposis and biological agents: the ARIA-ITALY Survey

Author

Lombardi, C., primary, Passalacqua, G., additional, Menzella, F., additional, Mauritz Canevari, R.F, additional, Danesi, G., additional, Pusateri, A.M., additional, Carone, M., additional, Vancheri, C., additional, Di Marco, F., additional, Micheletto, C., additional, Manzotti, G., additional, Di Gioacchino, M, additional, Bilò, M.B, additional, Gelardi, M, additional, Senna, G, additional, Canonica, G.W, additional, and Italy Panel, ARIA, additional

Published
2024
Full Text
View/download PDF

9. Obtention d’une rémission clinique dans l’asthme sévère après un traitement par mépolizumab : résultats de l’étude REALITI-A à 2 ans

Author

Brusselle, G., primary, Lougheed, D., additional, Canonica, G.W., additional, Munoz-Esquerre, M., additional, Heaney, L.G., additional, Price, R.G., additional, Howarth, P., additional, Raimondi, A., additional, Gardiner, F., additional, Chupp, G., additional, Welte, T., additional, and Picaud, C., additional

Published
2024
Full Text
View/download PDF

10. EPH200 Healthcare Resource Consumption of Patients with Chronic Obstructive Pulmonary Disease Treated with Triple and Dual Therapy and Experiencing an Acute Exacerbation

Author

Calabria, S., primary, Ronconi, G., additional, Dondi, L., additional, Piccinni, C., additional, Dell'Anno, I., additional, Pedrini, A., additional, Esposito, I., additional, Brignoli, O., additional, Canonica, G.W., additional, Carone, M., additional, Di Marco, F., additional, Micheletto, C., additional, Vancheri, C., additional, and Martini, N., additional

Published
2023
Full Text
View/download PDF

11. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

Author

Bousquet, J., Hellings, P.W., Aberer, W., Agache, I., Akdis, C.A., Akdis, M., Alberti, M.R., Almeida, R., Amat, F., Angles, R., Annesi-Maesano, I., Ansotegui, I.J., Anto, J.M., Arnavielle, S., Asayag, E., Asarnoj, A., Arshad, H., Avolio, F., Bacci, E., Bachert, C., Baiardini, I., Barbara, C., Barbagallo, M., Baroni, I., Barreto, B.A., Basagana, X., Bateman, E.D., Bedolla-Barajas, M., Bedbrook, A., Bewick, M., Beghé, B., Bel, E.H., Bergmann, K.C., Bennoor, K.S., Benson, M., Bertorello, L., Białoszewski, A.Z., Bieber, T., Bialek, S., Bindslev-Jensen, C., Bjermer, L., Blain, H., Blasi, F., Blua, A., Bochenska Marciniak, M., Bogus-Buczynska, I., Boner, A.L., Bonini, M., Bonini, S., Bosnic-Anticevich, C.S., Bosse, I., Bouchard, J., Boulet, L.P., Bourret, R., Bousquet, P.J., Braido, F., Briedis, V., Brightling, C.E., Brozek, J., Bucca, C., Buhl, R., Buonaiuto, R., Panaitescu, C., Burguete Cabañas, M.T., Burte, E., Bush, A., Caballero-Fonseca, F., Caillot, D., Caimmi, D., Calderon, M.A., Camargos, P.A.M., Camuzat, T., Canfora, G., Canonica, G.W., Cardona, V., Carlsen, K.H., Carreiro-Martins, P., Carriazo, A.M., Carr, W., Cartier, C., Casale, T., Castellano, G., Cecchi, L., Cepeda Sarabia, A.M., Chavannes, N.H., Chen, Y., Chiron, R., Chivato, T., Chkhartishvili, E., Chuchalin, A.G., Chung, K.F., Ciaravolo, M.M., Ciceran, A., Cingi, C., Ciprandi, G., Carvalho Coehlo, A.C., Colas, L., Colgan, E., Coll, J., Conforti, D., Correia de Sousa, J., Cortés-Grimaldo, R.M., Corti, F., Costa, E., Costa-Dominguez, M.C., Courbis, A.L., Cox, L., Crescenzo, M., Cruz, A.A., Custovic, A., Czarlewski, W., Dahlen, S.E., Dario, C., da Silva, J., Dauvilliers, Y., Darsow, U., De Blay, F., De Carlo, G., Dedeu, T., de Fátima Emerson, M., De Feo, G., De Vries, G., De Martino, B., de Paula Motta Rubini, N., Deleanu, D., Demoly, P., Denburg, J.A., Devillier, P., Di Capua Ercolano, S., Di Carluccio, N., Didier, A., Dokic, D., Dominguez-Silva, M.G., Douagui, H., Dray, G., Dubakiene, R., Durham, S.R., Du Toit, G., Dykewicz, M.S., El-Gamal, Y., Eklund, P., Eller, E., Emuzyte, R., Farrell, J., Farsi, A., Ferreira de Mello, J., Jr., Ferrero, J., Fink-Wagner, A., Fiocchi, A., Fokkens, W.J., Fonseca, J.A., Fontaine, J.F., Forti, S., Fuentes-Perez, J.M., Gálvez-Romero, J.L., Gamkrelidze, A., Garcia-Aymerich, J., García-Cobas, C.Y., Garcia-Cruz, M.H., Gemicioğlu, B., Genova, S., George, C., Gereda, J.E., Gerth van Wijk, R., Gomez, R.M., Gómez-Vera, J., González Diaz, S., Gotua, M., Grisle, I., Guidacci, M., Guldemond, N.A., Gutter, Z., Guzmán, M.A., Haahtela, T., Hajjam, J., Hernández, L., Hourihane, J.O.'B., Huerta-Villalobos, Y.R., Humbert, M., Iaccarino, G., Illario, M., Ivancevich, J.C., Jares, E.J., Jassem, E., Johnston, S.L., Joos, G., Jung, K.S., Jutel, M., Kaidashev, I., Kalayci, O., Kalyoncu, A.F., Karjalainen, J., Kardas, P., Keil, T., Keith, P.K., Khaitov, M., Khaltaev, N., Kleine-Tebbe, J., Klimek, L., Kowalski, M.L., Kuitunen, M., Kull, I., Kuna, P., Kupczyk, M., Kvedariene, V., Krzych-Fałta, E., Lacwik, P., Larenas-Linnemann, D., Laune, D., Lauri, D., Lavrut, J., Le, L.T.T., Lessa, M., Levato, G., Li, J., Lieberman, P., Lipiec, A., Lipworth, B., Lodrup Carlsen, K.C., Louis, R., Lourenço, O., Luna-Pech, J.A., Maciej, K., Magnan, A., Mahboub, B., Maier, D., Mair, A., Majer, I., Malva, J., Mandajieva, E., Manning, P., De Manuel Keenoy, E., Marshall, G.D., Masjedi, M.R., Maspero, J.F., Mathieu-Dupas, E., Matta Campos, J.J., Matos, A.L., Maurer, M., Mavale-Manuel, S., Mayora, O., Medina-Avalos, M.A., Melén, E., Melo-Gomes, E., Meltzer, E.O., Menditto, E., Mercier, J., Miculinic, N., Mihaltan, F., Milenkovic, B., Moda, G., Mogica-Martinez, M.D., Mohammad, Y., Momas, I., Montefort, S., Monti, R., Mora Bogado, D., Morais-Almeida, M., Morato-Castro, F.F., Mösges, R., Mota-Pinto, A., Moura Santo, P., Mullol, J., Münter, L., Muraro, A., Murray, R., Naclerio, R., Nadif, R., Nalin, M., Napoli, L., Namazova-Baranova, L., Neffen, H., Niedeberger, V., Nekam, K., Neou, A., Nieto, A., Nogueira-Silva, L., Nogues, M., Novellino, E., Nyembue, T.D., O'Hehir, R.E., Odzhakova, C., Ohta, K., Okamoto, Y., Okubo, K., Onorato, G.L., Ortega Cisneros, M., Ouedraogo, S., Pali-Schöll, I., Palkonen, S., Panzner, P., Papadopoulos, N.G., Park, H.S., Papi, A., Passalacqua, G., Paulino, E., Pawankar, R., Pedersen, S., Pépin, J.L., Pereira, A.M., Persico, M., Pfaar, O., Phillips, J., Picard, R., Pigearias, B., Pin, I., Pitsios, C., Plavec, D., Pohl, W., Popov, T.A., Portejoie, F., Potter, P., Pozzi, A.C., Price, D., Prokopakis, E.P., Puy, R., Pugin, B., Pulido Ross, R.E., Przemecka, M., Rabe, K.F., Raciborski, F., Rajabian-Soderlund, R., Reitsma, S., Ribeirinho, I., Rimmer, J., Rivero-Yeverino, D., Rizzo, J.A., Rizzo, M.C., Robalo-Cordeiro, C., Rodenas, F., Rodo, X., Rodriguez Gonzalez, M., Rodriguez-Mañas, L., Rolland, C., Rodrigues Valle, S., Roman Rodriguez, M., Romano, A., Rodriguez-Zagal, E., Rolla, G., Roller-Wirnsberger, R.E., Romano, M., Rosado-Pinto, J., Rosario, N., Rottem, M., Ryan, D., Sagara, H., Salimäki, J., Samolinski, B., Sanchez-Borges, M., Sastre-Dominguez, J., Scadding, G.K., Schunemann, H.J., Scichilone, N., Schmid-Grendelmeier, P., Serpa, F.S., Shamai, S., Sheikh, A., Sierra, M., Simons, F.E.R., Siroux, V., Sisul, J.C., Skrindo, I., Solé, D., Somekh, D., Sondermann, M., Sooronbaev, T., Sova, M., Sorensen, M., Sorlini, M., Spranger, O., Stellato, C., Stelmach, R., Stukas, R., Sunyer, J., Strozek, J., Szylling, A., Tebyriçá, J.N., Thibaudon, M., To, T., Todo-Bom, A., Tomazic, P.V., Toppila-Salmi, S., Trama, U., Triggiani, M., Suppli Ulrik, C., Urrutia-Pereira, M., Valenta, R., Valero, A., Valiulis, A., Valovirta, E., van Eerd, M., van Ganse, E., van Hague, M., Vandenplas, O., Ventura, M.T., Vezzani, G., Vasankari, T., Vatrella, A., Verissimo, M.T., Viart, F., Viegi, M., Vicheva, D., Vontetsianos, T., Wagenmann, M., Walker, S., Wallace, D., Wang, D.Y., Waserman, S., Werfel, T., Westman, M., Wickman, M., Williams, D.M., Williams, S., Wilson, N., Wright, J., Wroczynski, P., Yakovliev, P., Yawn, B.P., Yiallouros, P.K., Yorgancioglu, A., Yusuf, O.M., Zar, H.J., Zhang, L., Zhong, N., Zernotti, M.E., Zidarn, M., Zuberbier, T., Zubrinich, C., Zurkuhlen, A., Bousquet, Jean, Hellings, Peter W., Agache, Ioana, Amat, Flore, Annesi-Maesano, Isabella, Ansotegui, Ignacio J., Anto, Josep M., Bachert, Claus, Bateman, Eric D., Bedbrook, Anna, Bennoor, Kazi, Bewick, Mickael, Bindslev-Jensen, Carsten, Bosnic-Anticevich, Sinthia, Bosse, Isabelle, Brozek, Jan, Brussino, Luisa, Canonica, Giorgio W., Cardona, Victoria, Casale, Thomas, Cepeda Sarabia, Alfonso M., Chavannes, Niels H., Cecchi, Lorenzo, Correia de Sousa, Jaime, Costa, Elisio, Cruz, Alvaro A., Czarlewski, Wienczyslawa, De Carlo, Giuseppe, De Feo, Giulia, Demoly, Pascal, Devillier, Philippe, Dykewicz, Mark S., El-Gamal, Yehia, Eller, Esben E., Fonseca, Joao A., Fontaine, Jean-François, Fokkens, Wytske J., Guzmán, Maria-Antonieta, Haahtela, Tari, Illario, Maddalena, Ivancevich, Juan-Carlos, Just, Jocelyne, Kaidashev, Igor, Khaitov, Musa, Kalayci, Omer, Keil, Thomas, Klimek, Ludger, Kowalski, Marek L., Kuna, Piotr, Kvedariene, Violeta, Larenas-Linnemann, Desiree, Laune, Daniel, Le, Lan T.T., Carlsen, Karin Lodrup, Lourenço, Olga, Mahboub, Bassam, Mair, Alpana, Menditto, Enrica, Milenkovic, Branislava, Morais-Almeida, Mario, Mösges, Ralph, Mullol, Joaquim, Murray, Ruth, Naclerio, Robert, Namazova-Baranova, Leyla, Novellino, Ettore, O'Hehir, Robyn E., Ohta, Ken, Okamoto, Yoshitaka, Okubo, Kimi, Onorato, Gabrielle L., Palkonen, Susanna, Panzner, Petr, Papadopoulos, Nikos G., Park, Hae-Sim, Paulino, Ema, Pawankar, Ruby, Pfaar, Oliver, Plavec, Davor, Popov, Ted A., Potter, Paul, Prokopakis, Emmanuel P., Rottem, Menachem, Ryan, Dermot, Salimäki, Johanna, Samolinski, Boleslaw, Sanchez-Borges, Mario, Schunemann, Holger J., Sheikh, Aziz, Sisul, Juan-Carlos, Rajabian-Söderlund, Rojin, Sooronbaev, Talant, Stellato, Cristiana, To, Teresa, Todo-Bom, Ana-Maria, Tomazic, Peter-Valentin, Toppila-Salmi, Sanna, Valero, Antonio, Valiulis, Arunas, Valovirta, Erkka, Ventura, Maria-Teresa, Wagenmann, Martin, Wang, De Yun, Wallace, Dana, Waserman, Susan, Wickman, Magnus, Yorgancioglu, Arzu, Zhang, Luo, Zhong, Nanshan, Zidarn, Mihaela, and Zuberbier, Torsten

Published
2019
Full Text
View/download PDF

21. EUFOREA treatment algorithm for allergic rhinitis.

Author

Hellings P.W., Bachert C., Bjermer L., Canonica G.W., Cardell L.O., Carney A.S., Constantinidis J., Deneyer L., Diamant Z., Durham S., Gevaert P., Harvey R., Hopkins C., Kjeldsen A., Klimek L., Lund V.J., Price D., Rimmer J., Ryan D., Roberts G., Sahlstrand-Johnson P., Salmi S., Samji M., Scadding G., Smith P., Steinsvik A., Wagenmann M., Seys S., Wahn U., Fokkens W.J., Hellings P.W., Bachert C., Bjermer L., Canonica G.W., Cardell L.O., Carney A.S., Constantinidis J., Deneyer L., Diamant Z., Durham S., Gevaert P., Harvey R., Hopkins C., Kjeldsen A., Klimek L., Lund V.J., Price D., Rimmer J., Ryan D., Roberts G., Sahlstrand-Johnson P., Salmi S., Samji M., Scadding G., Smith P., Steinsvik A., Wagenmann M., Seys S., Wahn U., and Fokkens W.J.

Published
2022

24. Development and validation of combined symptom-medication scores for allergic rhinitis*

Author

Sousa-Pinto, B. Azevedo, L.F. Jutel, M. Agache, I. Canonica, G.W. Czarlewski, W. Papadopoulos, N.G. Bergmann, K.-C. Devillier, P. Laune, D. Klimek, L. Anto, A. Anto, J.M. Eklund, P. Almeida, R. Bedbrook, A. Bosnic-Anticevich, S. Brough, H.A. Brussino, L. Cardona, V. Casale, T. Cecchi, L. Charpin, D. Chivato, T. Costa, E.M. Cruz, A.A. Dramburg, S. Durham, S.R. De Feo, G. Gerth van Wijk, R. Fokkens, W.J. Gemicioglu, B. Haahtela, T. Illario, M. Ivancevich, J.C. Kvedariene, V. Kuna, P. Larenas-Linnemann, D.E. Makris, M. Mathieu-Dupas, E. Melén, E. Morais-Almeida, M. Mösges, R. Mullol, J. Nadeau, K.C. Pham-Thi, N. O’Hehir, R. Regateiro, F.S. Reitsma, S. Samolinski, B. Sheikh, A. Stellato, C. Todo-Bom, A. Tomazic, P.V. Toppila-Salmi, S. Valero, A. Valiulis, A. Ventura, M.T. Wallace, D. Waserman, S. Yorgancioglu, A. De Vries, G. van Eerd, M. Zieglmayer, P. Zuberbier, T. Pfaar, O. Almeida Fonseca, J. Bousquet, J.

Abstract

Background: Validated combined symptom-medication scores (CSMSs) are needed to investigate the effects of allergic rhinitis treatments. This study aimed to use real-life data from the MASK-air® app to generate and validate hypothesis- and data-driven CSMSs. Methods: We used MASK-air® data to assess the concurrent validity, test-retest reliability and responsiveness of one hypothesis-driven CSMS (modified CSMS: mCSMS), one mixed hypothesis- and data-driven score (mixed score), and several data-driven CSMSs. The latter were generated with MASK-air® data following cluster analysis and regression models or factor analysis. These CSMSs were compared with scales measuring (i) the impact of rhinitis on work productivity (visual analogue scale [VAS] of work of MASK-air®, and Work Productivity and Activity Impairment: Allergy Specific [WPAI-AS]), (ii) quality-of-life (EQ-5D VAS) and (iii) control of allergic diseases (Control of Allergic Rhinitis and Asthma Test [CARAT]). Results: We assessed 317,176 days of MASK-air® use from 17,780 users aged 16-90 years, in 25 countries. The mCSMS and the factor analyses-based CSMSs displayed poorer validity and responsiveness compared to the remaining CSMSs. The latter displayed moderate-to-strong correlations with the tested comparators, high test-retest reliability and moderate-to-large responsiveness. Among data-driven CSMSs, a better performance was observed for cluster analyses-based CSMSs. High accuracy (capacity of discriminating different levels of rhinitis control) was observed for the latter (AUC-ROC = 0.904) and for the mixed CSMS (AUC-ROC = 0.820). Conclusion: The mixed CSMS and the cluster-based CSMSs presented medium-high validity, reliability and accuracy, rendering them as candidates for primary endpoints in future rhinitis trials. © 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Published
2022

25. Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model

Author

Sousa-Pinto, B. Azevedo, L.F. Sá-Sousa, A. Vieira, R.J. Amaral, R. Klimek, L. Czarlewski, W. Anto, J.M. Bedbrook, A. Kvedariene, V. Ventura, M.T. Ansotegui, I.J. Bergmann, K.-C. Brussino, L. Canonica, G.W. Cardona, V. Carreiro-Martins, P. Casale, T. Cecchi, L. Chivato, T. Chu, D.K. Cingi, C. Costa, E.M. Cruz, A.A. De Feo, G. Devillier, P. Fokkens, W.J. Gaga, M. Gemicioğlu, B. Haahtela, T. Ivancevich, J.C. Ispayeva, Z. Jutel, M. Kuna, P. Kaidashev, I. Kraxner, H. Larenas-Linnemann, D.E. Laune, D. Lipworth, B. Louis, R. Makris, M. Monti, R. Morais-Almeida, M. Mösges, R. Mullol, J. Odemyr, M. Okamoto, Y. Papadopoulos, N.G. Patella, V. Pham-Thi, N. Regateiro, F.S. Reitsma, S. Rouadi, P.W. Samolinski, B. Sova, M. Todo-Bom, A. Taborda-Barata, L. Tomazic, P.V. Toppila-Salmi, S. Sastre, J. Tsiligianni, I. Valiulis, A. Wallace, D. Waserman, S. Yorgancioglu, A. Zidarn, M. Zuberbier, T. Fonseca, J.A. Bousquet, J. Pfaar, O.

Abstract

Background: Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies. Objective: To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air® app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT. Methods: We assessed the MASK-air® data of European users with self-reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales—VASs), and a combined symptom-medication score (CSMS). We applied Bayesian mixed-effects models, with clustering by patient, country and pollen season. Results: We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT-tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = −12.1;−2.8), lower VAS Work (average difference = 5.0; 95%CrI = −8.5;−1.5), and a lower CSMS (average difference = 3.7; 95%CrI = −9.3;2.2). When compared to SCIT, SLIT-tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = −17.2;−2.8), lower VAS Work (average difference = 7.8; 95%CrI = −15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = −18.5;0.2). Conclusion: In patients with grass pollen allergy, SLIT-tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally-harmonised standards for performing and reporting real-world data in AIT are needed to better understand its ‘real-world’ effectiveness. © 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.

Published
2022

26. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

Author

Porsbjerg, C.M. Menzies-Gow, A.N. Tran, T.N. Murray, R.B. Unni, B. Audrey Ang, S.L. Alacqua, M. Al-Ahmad, M. Al-Lehebi, R. Altraja, A. Belevskiy, A.S. Björnsdóttir, U.S. Bourdin, A. Busby, J. Canonica, G.W. Christoff, G.C. Cosio, B.G. Costello, R.W. FitzGerald, J.M. Fonseca, J.A. Hansen, S. Heaney, L.G. Heffler, E. Hew, M. Iwanaga, T. Jackson, D.J. Kocks, J.W.H. Kallieri, M. Bruce Ko, H.-K. Koh, M.S. Larenas-Linnemann, D. Lehtimäki, L.A. Loukides, S. Lugogo, N. Maspero, J. Papaioannou, A.I. Perez-de-Llano, L. Pitrez, P.M. Popov, T.A. Rasmussen, L.M. Rhee, C.K. Sadatsafavi, M. Schmid, J. Siddiqui, S. Taillé, C. Taube, C. Torres-Duque, C.A. Ulrik, C. Upham, J.W. Wang, E. Wechsler, M.E. Bulathsinhala, L. Carter, V. Chaudhry, I. Eleangovan, N. Hosseini, N. Rowlands, M.-A. Price, D.B. van Boven, J.F.M.

Abstract

Background: Regulatory bodies have approved five biologics for severe asthma. However, regional differences in accessibility may limit the global potential for personalized medicine. Objective: To compare global differences in ease of access to biologics. Methods: In April 2021, national prescription criteria for omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab were reviewed by severe asthma experts collaborating in the International Severe Asthma Registry. Outcomes (per country, per biologic) were (1) country-specific prescription criteria and (2) development of the Biologic Accessibility Score (BACS). The BACS composite score incorporates 10 prescription criteria, each with a maximum score of 10 points. Referenced to European Medicines Agency marketing authorization specifications, a higher score reflects easier access. Results: Biologic prescription criteria differed substantially across 28 countries from five continents. Blood eosinophil count thresholds (usually ≥300 cells/μL) and exacerbations were key requirements for anti-IgE/anti–IL-5/5R prescriptions in around 80% of licensed countries. Most countries (40% for dupilumab to 54% for mepolizumab) require two or more moderate or severe exacerbations, whereas numbers ranged from none to four. Moreover, 0% (for reslizumab) to 21% (for omalizumab) of countries required long-term oral corticosteroid use. The BACS highlighted marked between-country differences in ease of access. For omalizumab, mepolizumab, benralizumab, and dupilumab, only two, one, four, and seven countries, respectively, scored equal or higher than the European Medicines Agency reference BACS. For reslizumab, all countries scored lower. Conclusions: Although some differences were expected in country-specific biologic prescription criteria and ease of access, the substantial differences found in the current study present a challenge to implementing precision medicine across the world. © 2022 The Authors

Published
2022

27. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air® real-world data

Author

Sousa-Pinto, B. Sá-Sousa, A. Vieira, R.J. Amaral, R. Klimek, L. Czarlewski, W. Antó, J.M. Pfaar, O. Bedbrook, A. Kvedariene, V. Ventura, M.T. Ansotegui, I.J. Bergmann, K.-C. Brussino, L. Canonica, G.W. Cardona, V. Carreiro-Martins, P. Casale, T. Cecchi, L. Chivato, T. Chu, D.K. Cingi, C. Costa, E.M. Cruz, A.A. De Feo, G. Devillier, P. Fokkens, W.J. Gaga, M. Gemicioğlu, B. Haahtela, T. Ivancevich, J.C. Ispayeva, Z. Jutel, M. Kuna, P. Kaidashev, I. Kraxner, H. Larenas-Linnemann, D.E. Laune, D. Lipworth, B. Louis, R. Makris, M. Monti, R. Morais-Almeida, M. Mösges, R. Mullol, J. Odemyr, M. Okamoto, Y. Papadopoulos, N.G. Patella, V. Pham-Thi, N. Regateiro, F.S. Reitsma, S. Rouadi, P.W. Samolinski, B. Sova, M. Todo-Bom, A. Taborda-Barata, L. Tomazic, P.V. Toppila-Salmi, S. Sastre, J. Tsiligianni, I. Valiulis, A. Vandenplas, O. Wallace, D. Waserman, S. Yorgancioglu, A. Zidarn, M. Zuberbier, T. Fonseca, J.A. Bousquet, J.

Abstract

Background: Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data. Methods: We analysed 2015–2020 MASK-air® European data. We compared days under no medication, monotherapy and co-medication using the visual analogue scale (VAS) levels for overall allergic symptoms (‘VAS Global Symptoms’) and impact of AR on work. We assessed the monthly use of different medication schemes, performing separate analyses by region (defined geographically or by Google Trends patterns). We estimated the average number of different drugs reported per patient within 1 year. Results: We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy and 38,315 (17.3%) under co-medication. The median ‘VAS Global Symptoms’ was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p

Published
2022

28. Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air

Author

Agache, I., Basagaña, X., Bédard, A., Bergmann, K.C., Bindslev-Jensen, C., Blain, H., Bosnic-Anticevich, S., Bosse, I., Boulet, L.P., Brussino, L., Camargos, P., Canonica, G.W., Carreiro-Martins, P., Cardona, V., Cecchi, L., Chu, D., Costa, E., Cruz, A.A., da Silva, J., De Vries, G., Devillier, P., Fokkens, W.J., Fontaine, J.F., Fuentes-Pérez, J.-M., Gemicioğlu, B., Haahtela, T., Huerta-Villalobos, Y.R., Ivancevich, J.C., Jutel, M., Kaidashev, I., Khaitov, M., Klimek, L., Kraxner, H., Kuna, P., Kvedariene, V., Larenas-Linnemann, D.E.S., Laune, D., Lipworth, B., Manning, P., Makris, M., Melén, E., Morais-Almeida, M., Mösges, R., Mullol, J., Nekam, K., Niedoszytko, M., O'Hehir, R.E., Okamoto, Y., Papadopoulos, N.G., Patella, V., Pfaar, O., Pham-Thi, N., Regateiro, F.S., Reitsma, S., Rouadi, P.W., Samolinski, B., Sarquis-Serpa, F., Sastre, J., Scichilone, N., Stelmach, R., Suppli-Ulrik, C., Todo-Bom, A., Tomazic, P.V., Toppila-Salmi, S., Tsigiliani, I., Valero, A., Valiulis, A., Valovirta, E., van Eerd, M., Ventura, M.T., Waserman, S., Yorgancioglu, A., Zidarn, M., Sousa-Pinto, Bernardo, Sá-Sousa, Ana, Amaral, Rita, Czarlewski, Wienczyslawa, Bedbrook, Anna, Anto, Josep M., Bousquet, Jean, and Fonseca, João Almeida

Published
2022
Full Text
View/download PDF

30. Étude prospective internationale en vie réelle du mépolizumab chez les patients souffrant d’asthme sévère à un an: REALITI-A

Author

Pilette, C., primary, Canonica, G.W., additional, Chaudhuri, R., additional, Lee, F.E.H., additional, Lee, J.K., additional, Almonacid Sanchez, C., additional, Alfonso-Cristancho, R., additional, Jakes, R., additional, Maxwell, A., additional, Price, R., additional, Howarth, P., additional, and Chemla Seydoux, S., additional

Published
2022
Full Text
View/download PDF

31. Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air

Author

Sousa-Pinto, Bernardo, primary, Sá-Sousa, Ana, additional, Amaral, Rita, additional, Czarlewski, Wienczyslawa, additional, Bedbrook, Anna, additional, Anto, Josep M., additional, Bousquet, Jean, additional, Fonseca, João Almeida, additional, Agache, I., additional, Basagaña, X., additional, Bédard, A., additional, Bergmann, K.C., additional, Bindslev-Jensen, C., additional, Blain, H., additional, Bosnic-Anticevich, S., additional, Bosse, I., additional, Boulet, L.P., additional, Brussino, L., additional, Camargos, P., additional, Canonica, G.W., additional, Carreiro-Martins, P., additional, Cardona, V., additional, Cecchi, L., additional, Chu, D., additional, Costa, E., additional, Cruz, A.A., additional, da Silva, J., additional, De Vries, G., additional, Devillier, P., additional, Fokkens, W.J., additional, Fontaine, J.F., additional, Fuentes-Pérez, J.-M., additional, Gemicioğlu, B., additional, Haahtela, T., additional, Huerta-Villalobos, Y.R., additional, Ivancevich, J.C., additional, Jutel, M., additional, Kaidashev, I., additional, Khaitov, M., additional, Klimek, L., additional, Kraxner, H., additional, Kuna, P., additional, Kvedariene, V., additional, Larenas-Linnemann, D.E.S., additional, Laune, D., additional, Lipworth, B., additional, Manning, P., additional, Makris, M., additional, Melén, E., additional, Morais-Almeida, M., additional, Mösges, R., additional, Mullol, J., additional, Nekam, K., additional, Niedoszytko, M., additional, O'Hehir, R.E., additional, Okamoto, Y., additional, Papadopoulos, N.G., additional, Patella, V., additional, Pfaar, O., additional, Pham-Thi, N., additional, Regateiro, F.S., additional, Reitsma, S., additional, Rouadi, P.W., additional, Samolinski, B., additional, Sarquis-Serpa, F., additional, Sastre, J., additional, Scichilone, N., additional, Stelmach, R., additional, Suppli-Ulrik, C., additional, Todo-Bom, A., additional, Tomazic, P.V., additional, Toppila-Salmi, S., additional, Tsigiliani, I., additional, Valero, A., additional, Valiulis, A., additional, Valovirta, E., additional, van Eerd, M., additional, Ventura, M.T., additional, Waserman, S., additional, Yorgancioglu, A., additional, and Zidarn, M., additional

Published
2022
Full Text
View/download PDF

33. Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19

Author

Bousquet, J. Czarlewski, W. Zuberbier, T. Mullol, J. Blain, H. Cristol, J.-P. De La Torre, R. Pizarro Lozano, N. Le Moing, V. Bedbrook, A. Agache, I. Akdis, C.A. Canonica, G.W. Cruz, A.A. Fiocchi, A. Fonseca, J.A. Fonseca, S. Gemicioǧlu, B. Haahtela, T. Iaccarino, G. Ivancevich, J.C. Jutel, M. Klimek, L. Kraxner, H. Kuna, P. Larenas-Linnemann, D.E. Martineau, A. Melén, E. Okamoto, Y. Papadopoulos, N.G. Pfaar, O. Regateiro, F.S. Reynes, J. Rolland, Y. Rouadi, P.W. Samolinski, B. Sheikh, A. Toppila-Salmi, S. Valiulis, A. Choi, H.-J. Kim, H.J. Anto, J.M.

Subjects
nervous system, musculoskeletal, neural, and ocular physiology, food and beverages, psychological phenomena and processes
Abstract

In this article, we propose that differences in COVID-19 morbidity may be associated with transient receptor potential ankyrin 1 (TRPA1) and/or transient receptor potential vanilloid 1 (TRPV1) activation as well as desensitization. TRPA1 and TRPV1 induce inflammation and play a key role in the physiology of almost all organs. They may augment sensory or vagal nerve discharges to evoke pain and several symptoms of COVID-19, including cough, nasal obstruction, vomiting, diarrhea, and, at least partly, sudden and severe loss of smell and taste. TRPA1 can be activated by reactive oxygen species and may therefore be up-regulated in COVID-19. TRPA1 and TRPV1 channels can be activated by pungent compounds including many nuclear factor (erythroid-derived 2) (Nrf2)-interacting foods leading to channel desensitization. Interactions between Nrf2-associated nutrients and TRPA1/TRPV1 may be partly responsible for the severity of some of the COVID-19 symptoms. The regulation by Nrf2 of TRPA1/TRPV1 is still unclear, but suggested from very limited clinical evidence. In COVID-19, it is proposed that rapid desensitization of TRAP1/TRPV1 by some ingredients in foods could reduce symptom severity and provide new therapeutic strategies. © 2021 S. Karger AG, Basel.

Published
2021

34. Spices to Control COVID-19 Symptoms: Yes, but Not Only

Author

Bousquet, J. Czarlewski, W. Zuberbier, T. Mullol, J. Blain, H. Cristol, J.-P. De La Torre, R. Le Moing, V. Lozano, N.P. Bedbrook, A. Agache, I. Akdis, C.A. Canonica, G.W. Cruz, A.A. Fiocchi, A. Fonseca, J.A. Fonseca, S. Gemicioǧlu, B. Haahtela, T. Iaccarino, G. Ivancevich, J.C. Jutel, M. Klimek, L. Kuna, P. Larenas-Linnemann, D.E. Melén, E. Okamoto, Y. Papadopoulos, N.G. Pfaar, O. Reynes, J. Rolland, Y. Rouadi, P.W. Samolinski, B. Sheikh, A. Toppila-Salmi, S. Valiulis, A. Choi, H.-J. Kim, H.J. Anto, J.M.

Abstract

There are large country variations in COVID-19 death rates that may be partly explained by diet. Many countries with low COVID-19 death rates have a common feature of eating large quantities of fermented vegetables such as cabbage and, in some continents, various spices. Fermented vegetables and spices are agonists of the antioxidant transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2), and spices are transient receptor potential ankyrin 1 and vanillin 1 (TRPA1/V1) agonists. These mechanisms may explain many COVID-19 symptoms and severity. It appears that there is a synergy between Nrf2 and TRPA1/V1 foods that may explain the role of diet in COVID-19. One of the mechanisms of COVID-19 appears to be an oxygen species (ROS)-mediated process in synergy with TRP channels, modulated by Nrf2 pathways. Spicy foods are likely to desensitize TRP channels and act in synergy with exogenous antioxidants that activate the Nrf2 pathway. © 2020

Published
2021

35. EAACI Biologicals Guidelines—Recommendations for severe asthma

Author

Agache, I. Akdis, C.A. Akdis, M. Canonica, G.W. Casale, T. Chivato, T. Corren, J. Chu, D.K. Del Giacco, S. Eiwegger, T. Flood, B. Firinu, D. Gern, J.E. Hamelmann, E. Hanania, N. Hernández-Martín, I. Knibb, R. Mäkelä, M. Nair, P. O’Mahony, L. Papadopoulos, N.G. Papi, A. Park, H.-S. Pérez de Llano, L. Pfaar, O. Quirce, S. Sastre, J. Shamji, M. Schwarze, J. Palomares, O. Jutel, M.

Abstract

Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2021

36. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

Author

Pfaar, O. Klimek, L. Jutel, M. Akdis, C.A. Bousquet, J. Breiteneder, H. Chinthrajah, S. Diamant, Z. Eiwegger, T. Fokkens, W.J. Fritsch, H.-W. Nadeau, K.C. O’Hehir, R.E. O’Mahony, L. Rief, W. Sampath, V. Schedlowski, M. Torres, M.J. Traidl-Hoffmann, C. Wang, D.Y. Zhang, L. Bonini, M. Brehler, R. Brough, H.A. Chivato, T. Del Giacco, S.R. Dramburg, S. Gawlik, R. Gelincik, A. Hoffmann-Sommergruber, K. Hox, V. Knol, E.F. Lauerma, A. Matricardi, P.M. Mortz, C.G. Ollert, M. Palomares, O. Riggioni, C. Schwarze, J. Skypala, I. Untersmayr, E. Walusiak-Skorupa, J. Ansotegui, I.J. Bachert, C. Bedbrook, A. Bosnic-Anticevich, S. Brussino, L. Canonica, G.W. Cardona, V. Carreiro-Martins, P. Cruz, A.A. Czarlewski, W. Fonseca, J.A. Gotua, M. Haahtela, T. Ivancevich, J.C. Kuna, P. Kvedariene, V. Larenas-Linnemann, D.E. Abdul Latiff, A.H. Mäkelä, M. Morais-Almeida, M. Mullol, J. Naclerio, R. Ohta, K. Okamoto, Y. Onorato, G.L. Papadopoulos, N.G. Patella, V. Regateiro, F.S. Samoliński, B. Suppli Ulrik, C. Toppila-Salmi, S. Valiulis, A. Ventura, M.-T. Yorgancioglu, A. Zuberbier, T. Agache, I.

Subjects
education
Abstract

Background: The coronavirus disease 2019 (COVID-19) has evolved into a pandemic infectious disease transmitted by the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Allergists and other healthcare providers (HCPs) in the field of allergies and associated airway diseases are on the front line, taking care of patients potentially infected with SARS-CoV-2. Hence, strategies and practices to minimize risks of infection for both HCPs and treated patients have to be developed and followed by allergy clinics. Method: The scientific information on COVID-19 was analysed by a literature search in MEDLINE, PubMed, the National and International Guidelines from the European Academy of Allergy and Clinical Immunology (EAACI), the Cochrane Library, and the internet. Results: Based on the diagnostic and treatment standards developed by EAACI, on international information regarding COVID-19, on guidelines of the World Health Organization (WHO) and other international organizations, and on previous experience, a panel of experts including clinicians, psychologists, IT experts, and basic scientists along with EAACI and the “Allergic Rhinitis and its Impact on Asthma (ARIA)” initiative have developed recommendations for the optimal management of allergy clinics during the current COVID-19 pandemic. These recommendations are grouped into nine sections on different relevant aspects for the care of patients with allergies. Conclusions: This international Position Paper provides recommendations on operational plans and procedures to maintain high standards in the daily clinical care of allergic patients while ensuring the necessary safety measures in the current COVID-19 pandemic. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2021

37. Management of anaphylaxis due to COVID-19 vaccines in the elderly

Author

Bousquet, J. Agache, I. Blain, H. Jutel, M. Ventura, M.T. Worm, M. Del Giacco, S. Benetos, A. Bilo, B.M. Czarlewski, W. Abdul Latiff, A.H. Al-Ahmad, M. Angier, E. Annesi-Maesano, I. Atanaskovic-Markovic, M. Bachert, C. Barbaud, A. Bedbrook, A. Bennoor, K.S. Berghea, E.C. Bindslev-Jensen, C. Bonini, S. Bosnic-Anticevich, S. Brockow, K. Brussino, L. Camargos, P. Canonica, G.W. Cardona, V. Carreiro-Martins, P. Carriazo, A. Casale, T. Caubet, J.-C. Cecchi, L. Cherubini, A. Christoff, G. Chu, D.K. Cruz, A.A. Dokic, D. El-Gamal, Y. Ebisawa, M. Eberlein, B. Farrell, J. Fernandez-Rivas, M. Fokkens, W.J. Fonseca, J.A. Gao, Y. Gavazzi, G. Gawlik, R. Gelincik, A. Gemicioğlu, B. Gotua, M. Guérin, O. Haahtela, T. Hoffmann-Sommergruber, K. Hoffmann, H.J. Hofmann, M. Hrubisko, M. Illario, M. Irani, C. Ispayeva, Z. Ivancevich, J.C. Julge, K. Kaidashev, I. Khaitov, M. Knol, E. Kraxner, H. Kuna, P. Kvedariene, V. Lauerma, A. Le, L.T.T. Le Moing, V. Levin, M. Louis, R. Lourenco, O. Mahler, V. Martin, F.C. Matucci, A. Milenkovic, B. Miot, S. Montella, E. Morais-Almeida, M. Mortz, C.G. Mullol, J. Namazova-Baranova, L. Neffen, H. Nekam, K. Niedoszytko, M. Odemyr, M. O’Hehir, R.E. Okamoto, Y. Ollert, M. Palomares, O. Papadopoulos, N.G. Panzner, P. Passalacqua, G. Patella, V. Petrovic, M. Pfaar, O. Pham-Thi, N. Plavec, D. Popov, T.A. Recto, M.T. Regateiro, F.S. Reynes, J. Roller-Winsberger, R.E. Rolland, Y. Romano, A. Rondon, C. Rottem, M. Rouadi, P.W. Salles, N. Samolinski, B. Santos, A.F. S Sarquis, F. Sastre, J. M. G. A. Schols, J. Scichilone, N. Sediva, A. Shamji, M.H. Sheikh, A. Skypala, I. Smolinska, S. Sokolowska, M. Sousa-Pinto, B. Sova, M. Stelmach, R. Sturm, G. Suppli Ulrik, C. Todo-Bom, A.M. Toppila-Salmi, S. Tsiligianni, I. Torres, M. Untersmayr, E. Urrutia Pereira, M. Valiulis, A. Vitte, J. Vultaggio, A. Wallace, D. Walusiak-Skorupa, J. Wang, D.-Y. Waserman, S. Yorgancioglu, A. Yusuf, O.M. Zernotti, M. Zidarn, M. Chivato, T. Akdis, C.A. Zuberbier, T. Klimek, L.

Abstract

Older adults, especially men and/or those with diabetes, hypertension, and/or obesity, are prone to severe COVID-19. In some countries, older adults, particularly those residing in nursing homes, have been prioritized to receive COVID-19 vaccines due to high risk of death. In very rare instances, the COVID-19 vaccines can induce anaphylaxis, and the management of anaphylaxis in older people should be considered carefully. An ARIA-EAACI-EuGMS (Allergic Rhinitis and its Impact on Asthma, European Academy of Allergy and Clinical Immunology, and European Geriatric Medicine Society) Working Group has proposed some recommendations for older adults receiving the COVID-19 vaccines. Anaphylaxis to COVID-19 vaccines is extremely rare (from 1 per 100,000 to 5 per million injections). Symptoms are similar in younger and older adults but they tend to be more severe in the older patients. Adrenaline is the mainstay treatment and should be readily available. A flowchart is proposed to manage anaphylaxis in the older patients. © 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2021

39. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP

Author

Desrosiers, M., primary, Mannent, L.P., additional, Amin, N., additional, Canonica, G.W., additional, Hellings, P.W., additional, Gevaert, P., additional, Mullol, J., additional, Lee, S.E., additional, Fujieda, S., additional, Han, J.K., additional, Hopkins, C., additional, Fokkens, W., additional, Jankowski, R., additional, Cho, S.H., additional, Mao, X., additional, Zhang, M., additional, Rice, M.S., additional, Khan, A.H., additional, Kamat, S., additional, Patel, N., additional, Graham, N.M.H., additional, Ruddy, M., additional, and Bachert, C., additional

Published
2021
Full Text
View/download PDF

40. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

Author

Bousquet, J. Anto, J.M. Iaccarino, G. Czarlewski, W. Haahtela, T. Anto, A. Akdis, C.A. Blain, H. Canonica, G.W. Cardona, V. Cruz, A.A. Illario, M. Ivancevich, J.C. Jutel, M. Klimek, L. Kuna, P. Laune, D. Larenas-linnemann, D. Mullol, J. Papadopoulos, N.G. Pfaar, O. Samolinski, B. Valiulis, A. Yorgancioglu, A. Zuberbier, T. Latiff, A.H.A. Abdullah, B. Aberer, W. Abusada, N. Adcock, I. Afani, A. Agache, I. Aggelidis, X. Agustin, J. Akdis, C. Akdis, M. Al-Ahmad, M. Bassam, A.A.-Z. Aldrey-Palacios, O. Cuesta, E.A. Alzaabi, A. Amad, S. Ambrocio, G. Annesi-Maesano, I. Ansotegui, I. Anto, J. Arshad, H. Artesani, M.C. Asayag, E. Avolio, F. Azhari, K. Baiardini, I. Bajrović, N. Bakakos, P. Mongono, S.B. Balotro-Torres, C. Barba, S. Barbara, C. Barbosa, E. Barreto, B. Bartra, J. Bateman, E.D. Battur, L. Bedbrook, A. Barajas, M.B. Beghé, B. Bel, E. Kheder, A.B. Benson, M. Berghea, C. Bergmann, K.-C. Bernstein, D. Bewick, M. Bialek, S. Białoszewski, A. Bieber, T. Billo, N. Bilo, M.B. Bindslev-Jensen, C. Bjermer, L. Blain, H. Marciniak, M.B. Bond, C. Boner, A. Bonini, M. Bonini, S. Bosnic-Anticevich, S. Bosse, I. Botskariova, S. Bouchard, J. Boulet, L.-P. Bourret, R. Bousquet, P. Braido, F. Briggs, A. Brightling, C. Brozek, J. Buhl, R. Bumbacea, R. Cabañas, M.T.B. Bush, A. Busse, W.W. Buters, J. Caballero-Fonseca, F. Calderon, M.A. Calvo, M. Camargos, P. Camuzat, T. Cano, A. Capriles-Hulett, A. Caraballo, L. Cardona, V. Carlsen, K.-H. Caro, J. Carr, W. Carreon-Asun-cion, F. Carriazo, A.M. Casale, T. Castor, M.A. Castro, E. Cecchi, L. Sarabia, A.C. Chandrasekharan, R. Chang, Y.-S. Chato-Andeza, V. Chatzi, L. Chatzidaki, C. Chavannes, N.H. Chen, Y. Cheng, L. Chivato, T. Chkhartishvili, E. Christoff, G. Chrystyn, H. Chu, D.K. Chua, A. Chuchalin, A. Chung, K.F. Cicerán, A. Cingi, C. Ciprandi, G. Cirule, I. Coelho, A.C. Constantinidis, J. Sousa, J.C. Costa, E. Costa, D. Domínguez, M.C.C. Coste, A. Cox, L. Cruz, A.A. Cullen, J. Custovic, A. Cvetkovski, B. Czarlewski, W. D’amato, G. Silva, J.D. Dahl, R. Dahlen, S.-E. Daniilidis, V. Nahhas, L.D. Darsow, U. Blay, F. Guia, E.D. Santos, C. Keenoy, E.D.M. Vries, G.D. Deleanu, D. Demoly, P. Denburg, J. Devillier, P. Didier, A. Dimou, M. Dinh-Xuan, A.T. Djukanovic, R. Dokic, D. Silva, M.G.D. Douagui, H. Douladiris, N. Doulaptsi, M. Dray, G. Dubakiene, R. Durham, S. Dykewicz, M. Ebo, D. Edelbaher, N. Eklund, P. El-Gamal, Y. El-Sayed, Z.A. El-Sayed, S.S. El-Seify, M. Emuzyte, R. Enecilla, L. Espinoza, H. Farrell, J. Fernandez, L. Wagner, A.F. Fiocchi, A. Fokkens, W.J. Fontaine, J.-F. Forastiere, F. Fuentes, J.M. Gaerlan–resureccion, E. Gaga, M. Romero, J.L.G. Gamkrelidze, A. Garcia, A. Cobas, C.Y.G. Gayraud, J. Gemicioglu, B. Genova, S. Gereda, J. Wijk, R.G. Gomez, M. Diaz, S.G. Gotua, M. Grigoreas, C. Grisle, I. Guidacci, M. Guldemond, N. Gutter, Z. Guzmán, A. Haahtela, T. Halloum, R. Hamelmann, E. Hammadi, S. Harvey, R. Heinrich, J. Hejjaoui, A. Hellquist-Dahl, B. Velázquez, L.H. Hew, M. Hossny, E. Howarth, P. Hrubiško, M. Villalobos, Y.R.H. Humbert, M. Hyland, M. Iaccarino, G. Ibrahim, M. Illario, M. Ilyina, N. Irani, C. Ispayeva, Z. Ivancevich, J.C. Jares, E. Jarvis, D. Jassem, E. Jenko, K. Uscanga, R.D.J. Johnston, S. Joos, G. Jošt, M. Julge, K. Jung, K.-S. Just, J. Jutel, M. Kaidashev, I. Kalayci, O. Kalyoncu, F. Kapsali, J. Kardas, P. Karjalainen, J. Kasala, C.A. Katotomichelakis, M. Kazi, B. Keil, T. Keith, P. Khaitov, M. Khaltaev, N. Kim, Y.-Y. Kleine-Tebbe, J. Klimek, L. Koffi N’Goran, B. Kompoti, E. Kopač, P. Koppelman, G. Jeverica, A.K. Košnik, M. Kostov, K.V. Kowalski, M.L. Kralimarkova, T. Vrščaj, K.K. Kraxner, H. Kreft, S. Kritikos, V. Kudlay, D. Kull, I. Kuna, P. Kupczyk, M. Kvedariene, V. Kyriakakou, M. Lalek, N. Lane, S. Larenas-Linnemann, D. Latiff, A. Lau, S. Laune, D. Lavrut, J. Le, L. Lessa, M. Levin, M. Li, J. Lieberman, P. Liotta, G. Lipworth, B. Liu, X. Lobo, R. Lodrup Carlsen, K.C. Lombardi, C. Louis, R. Loukidis, S. Lourenço, O. Luna Pech, J.A. Madjar, B. Magnan, A. Mahboub, B. Mair, A. Mais, Y. van der Zee, A.-H.M. Makela, M. Makris, M. Malling, H.-J. Mandajieva, M. Manning, P. Manousakis, M. Maragoudakis, P. Marshall, G. Martins, P. Masjedi, M.R. Máspero, J.F. Campos, J.J.M. Maurer, M. Mavale-Manuel, S. Meço, C. Melén, E. Melo-Gomes, E. Meltzer, E.O. Menditto, E. Menzies-Gow, A. Merk, H. Michel, J.-P. Miculinic, N. Midão, L. Mihaltan, F. Mikael, K. Mikos, N. Milenkovic, B. Mitsias, D. Moalla, B. Moda, G. Martínez, M.D.M. Mohammad, Y. Moin, M. Molimard, M. Momas, I. Monaco, A. Montefort, S. Mora, D. Morais-Almeida, M. Mösges, R. Mostafa, B.E. Mullol, J. Münter, L. Muraro, A. Murray, R. Mustakov, T. Naclerio, R. Nadif, R. Nakonechna, A. Namazova-Baranova, L. Navarro-Locsin, G. Neffen, H. Nekam, K. Neou, A. Nicod, L. Niederberger-Leppin, V. Niedoszytko, M. Nieto, A. Novellino, E. Nunes, E. Nyembue, D. O’hehir, R. Odjakova, C. Ohta, K. Okamoto, Y. Okubo, K. Oliver, B. Onorato, G.L. Orru, M.P. Ouédraogo, S. Ouoba, K. Paggiaro, P.L. Pagkalos, A. Palaniappan, S.P. Pali-Schöll, I. Palkonen, S. Palmer, S. Bunu, C.P. Panzner, P. Papadopoulos, N.G. Papanikolaou, V. Papi, A. Paralchev, B. Paraskevopoulos, G. Park, H.S. Passalacqua, G. Patella, V. Pavord, I. Pawankar, R. Pedersen, S. Peleve, S. Pereira, A. Pérez, T. Pfaar, O. Pham-Thi, N. Pigearias, B. Pin, I. Piskou, K. Pitsios, C. Pitsios, K. Plavec, D. Poethig, D. Pohl, W. Susic, A.P. Popov, T.A. Portejoie, F. Potter, P. Poulsen, L. Prados-Torres, A. Prarros, F. Price, D. Prokopakis, E. Puy, R. Rabe, K. Raciborski, F. Ramos, J. Recto, M.T. Reda, S.M. Regateiro, F. Reider, N. Reitsma, S. Repka-Ramirez, S. Rimmer, J. Yeverino, D.R. Rizzo, J.A. Robalo-Cordeiro, C. Roberts, G. Roche, N. González, M.R. Zagal, E.R. Rolland, C. Roller-Wirns-berger, R. Rodriguez, M.R. Romano, A. Rombaux, P. Romualdez, J. Rosado-Pinto, J. Rosario, N. Rosenwasser, L. Rottem, M. Rouadi, P. Rovina, N. Sinur, I.R. Ruiz, M. Segura, L.T.R. Ryan, D. Sagara, H. Sakai, D. Sakurai, D. Saleh, W. Salimaki, J. Salina, H. Samitas, K.-N. Coronel, M.G.S. Sanchez-Borges, M. Sanchez-Lopez, J. Sarafoleanu, C. Serpa, F.S. Sastre-Dominguez, J. Scadding, G. Scheire, S. Schmid-Grendelmeier, P. Schuhl, J.F. Schunemann, H. Schvalbová, M. Scichilone, N. Sepúlveda, C. Serrano, E. Sheikh, A. Shields, M. Shishkov, V. Siafakas, N. Simeonov, A. Simons, E.F. Sisul, J.C. Sitkauskiene, B. Skrindo, I. Soklič, T. Solé, D. Sooronbaev, T. Soto-Martinez, M. Sova, M. Spertini, F. Spranger, O. Stamataki, S. Stefanaki, L. Stellato, C. Stelmach, R. Sterk, P. Strandberg, T. Stute, P. Subramaniam, A. Ulrik, C.S. Sutherland, M. Sylvestre, S. Syrigou, A. Barata, L.T. Takovska, N. Tan, R. Tan, F. Tan, V. Tang, I.P. Taniguchi, M. Tannert, L. Tattersall, J. Teixeira, M.D.C. Thijs, C. Thomas, M. To, T. Todo-Bom, A.M. Togias, A. Tomazic, P.-V. Toppila-Salmi, S. Toskala, E. Triggiani, M. Triller, N. Triller, K. Tsiligianni, I. Ulmeanu, R. Urbancic, J. Pereira, M.U. Vachova, M. Valdés, F. Valenta, R. Rostan, M.V. Valero, A. Valiulis, A. Vallianatou, M. Valovirta, E. Eerd, M.V. Ganse, E.V. Hage, M. Vandenplas, O. Vasankari, T. Vassileva, D. Ventura, M.T. Vera-Munoz, C. Vicheva, D. Vichyanond, P. Vidgren, P. Viegi, G. Vogelmeier, C. Hertzen, L.V. Vontetsianos, T. Vourdas, D. Wagenmann, M. Walker, S. Wallace, D. Wang, D.Y. Waserman, S. Wickman, M. Williams, S. Williams, D. Wilson, N. Woo, K. Wright, J. Wroczynski, P. Xepapadaki, P. Yakovliev, P. Yamaguchi, M. Yan, K. Yap, Y.Y. Yawn, B. Yiallouros, P. Yorgancioglu, A. Yoshihara, S. Young, I. Yusuf, O.B. Zaidi, A. Zaitoun, F. Zar, H. Zernotti, M. Zhang, L. Zhong, N. Zidarn, M. Zuberbier, T.

Abstract

Following publication of the original article [1], the authors identified an error in the affiliation list. The affiliation of author G. Walter Canonica should have been split up into two affiliations: • Personalized Medicine, Asthma and Allergy – Humanitas Clinical and Research Center – IRCCS, Rozzano (MI), Italy • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy The corrected affiliation list is reflected in this Correction. © 2020, The Author(s).

Published
2020

41. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement

Author

Bousquet, J. Akdis, C.A. Jutel, M. Bachert, C. Klimek, L. Agache, I. Ansotegui, I.J. Bedbrook, A. Bosnic-Anticevich, S. Canonica, G.W. Chivato, T. Cruz, A.A. Czarlewski, W. Del Giacco, S. Du, H. Fonseca, J.A. Gao, Y. Haahtela, T. Hoffmann-Sommergruber, K. Ivancevich, J.-C. Khaltaev, N. Knol, E.F. Kuna, P. Larenas-Linnemann, D. Mullol, J. Naclerio, R. Ohta, K. Okamoto, Y. O’Mahony, L. Onorato, G.L. Papadopoulos, N.G. Pfaar, O. Samolinski, B. Schwarze, J. Toppila-Salmi, S. Ventura, M.-T. Valiulis, A. Yorgancioglu, A. Zuberbier, T. Pawankar, R. Mubeccel, A. Mona, A.-A. Emilio, A.C. Hasan, A. Cristina, A.M. Zeinab, A. Mostafa, B.E. Sergio, B. Cristina, B. Eric, B. Bianca, B. Elisabeth, B. Larl-Christian, B. David, B. Leif, B. Attilio, B. Sergio, B. isabelle, B. Jacques, B. Louis-Philippe, B. Fulvio, B. Christopher, B. Roland, B. Carmen, B. Andrew, B. William, B. Fernan, C.-F. Davide, C. Silvia, C. Paulo, C. Walter, C. Vicky, C. Kai-Hakon, C. Warner, C. Thomas, C. Lorenzo, C. Alfonso, C.M. Niels, C. Ekaterine, C. George, C. Derek, C. Cemal, C. Giorgio, C. Ieva, C. Sousa Jaime, C.D. Maria del Carmen, C.D. André, C. Linda, C. Alvaro, C. Adnan, C. Ulf, D. Frédéric, D.B. Diana, D. Pascal, D. Philippe, D. Alain, D. Ratko, D. Maria, D.C.T. Dejan, D. Ruta, D. Stephen, D. Patrik, E. Yehia, E.-G. Regina, E. Bieren Julia, E.-V. Alessandro, F. Wytske, F. Mina, G. Luis, G.R.J. Bilun, G. Sonya, G. José, G. Maximiliano, G. Maia, G. Ineta, G. Marta, G. Antonieta, G.M. Adnan, H. Elham, H. Jonathan, H. Martin, H. Yunuen, H.V. Guido, I. Carla, I. Zhanat, I. Edgardo, J. Ewa, J. Erika, J.-J. Sebastian, J. Guy, J. Ki-Suck, J. Jocelyne, J. Igor, K. Omer, K. Fuat, K. Przemyslaw, K. Jussi, K. Jorg, K.-T. Gerard, K. Marek, K. Mikael, K. Violeta, K. Amir, L. Susanne, L. Lan, L. Marcus, L. Michael, L. Jing, L. Philip, L. Brian, L. Karin, L.C. Bassam, M. Mika, M. Hans-Jorgen, M. Gailen, M. Pedro, M. Mohammad, M. Juan-José, M. Cem, M. Erik, M. Eli, M. Hans, M. Jean-Pierre, M. Florin, M. Neven, M. Branislava, M. Yousser, M. Mathieu, M. Mario, M.-A. Ralph, M. Lars, M. Antonella, M. Tihomir, M. Alla, N. Leyla, N.-B. Kristof, N. Laurent, N. Robyn, O. Kimihiro, O. Brian, O. Luigi, P.P. Isabella, P.-S. Petr, P. Nilos, P. Sim, P.H. Ruby, P. Ana, P. Bernard, P. Constantinos, P. Davor, P. Wolfgang, P. Todor, P. Fabienne, P. Paul, P. Lars, P. Emmanuel, P. Claus, R. Stella, R.M. Janet, R. José Angelo, R. Graham, R. Nicolas, R. Antonino, R. Jose, R.-P. Nelson, R. Lanny, R. Philip, R. Dermot, R. Mario, S.-B. Joaquin, S.-D. Glenis, S. Elie, S. Nikolaos, S. Estelle, S. Juan-Carlos, S. Dirceu, S. Talant, S. Manuel, S.-M. Cristiana, S. Rafael, S. Timo, S. Charlotte, S.U. Carel, T. Peter-Valentin, T. Massimo, T. Ioana, T. Marilyn, U.P. Erkka, V. Eric, V.G. Marianne, V.H. Olivier, V. Petra, V. Martin, W. Dana, W. Yun, W.D. Susan, W. Magnus, W. Dennis, W. Barbara, Y. Arzu, Y. Osman, Y. Mario, Z. Mihaela, Z. the ARIA-MASK Study Group

Published
2020

42. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

Author

Agache, I. Rocha, C. Beltran, J. Song, Y. Posso, M. Solà, I. Alonso-Coello, P. Akdis, C. Akdis, M. Canonica, G.W. Casale, T. Chivato, T. Corren, J. Del Giacco, S. Eiwegger, T. Firinu, D. Gern, J.E. Hamelmann, E. Hanania, N. Mäkelä, M. Martín, I.H. Nair, P. O'Mahony, L. Papadopoulos, N.G. Papi, A. Park, H.-S. Pérez de Llano, L. Quirce, S. Sastre, J. Shamji, M. Schwarze, J. Canelo-Aybar, C. Palomares, O. Jutel, M.

Abstract

Allergic asthma is a frequent asthma phenotype. Both IgE and type 2 cytokines are increased, with some degree of overlap with other phenotypes. Systematic reviews assessed the efficacy and safety of benralizumab, dupilumab and omalizumab (alphabetical order) vs standard of care for patients with uncontrolled severe allergic asthma. PubMed, Embase and Cochrane Library were searched to identify RCTs and health economic evaluations, published in English. Critical and important asthma-related outcomes were evaluated. The risk of bias and the certainty of the evidence were assessed using GRADE. All three biologicals reduced with high certainty the annualized asthma exacerbation rate: benralizumab incidence rate ratios (IRR) 0.63 (95% CI 0.50 − 0.81); dupilumab IRR 0.58 (95%CI 0.47 − 0.73); and omalizumab IRR 0.56 (95%CI 0.42 − 0.73). Benralizumab and dupilumab improved asthma control with high certainty and omalizumab with moderate certainty; however, none reached the minimal important difference (MID). Both benralizumab and omalizumab improved QoL with high certainty, but only omalizumab reached the MID. Omalizumab enabled ICS dose reduction with high certainty. Benralizumab and omalizumab showed an increase in drug-related adverse events (AEs) with low to moderate certainty. All three biologicals had moderate certainty for an ICER/QALY value above the willingness to pay threshold. There was high certainty that in children 6-12 years old omalizumab decreased the annualized exacerbation rate [IRR 0.57 (95%CI 0.45-0.72)], improved QoL [relative risk 1.43 (95%CI 1.12 −1.83)], reduced ICS [mean difference (MD) −0.45 (95% CI −0.58 to −0.32)] and rescue medication use [MD −0.41 (95%CI −0.66 to −0.15)]. © 2020 John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2020

43. ARIA Guideline 2019: Treatment of allergic rhinitis in the German health system [ARIA-Leitlinie 2019: Behandlung der allergischen Rhinitis im deutschen Gesundheitssystem]

Author

Klimek, L. Bachert, C. Pfaar, O. Becker, S. Bieber, T. Brehler, R. Buhl, R. Casper, I. Chaker, A. Czech, W. Fischer, J. Fuchs, T. Gerstlauer, M. Hörmann, K. Jakob, T. Jung, K. Kopp, M.V. Mahler, V. Merk, H. Mülleneisen, N. Nemat, K. Rabe, U. Ring, J. Saloga, J. Schlenter, W. Schmidt-Weber, C. Seyfarth, H. Sperl, A. Spindler, T. Staubach, P. Strieth, S. Treudler, R. Vogelberg, C. Wallrafen, A. Wehrmann, W. Wrede, H. Zuberbier, T. Bedbrook, A. Canonica, G.W. Cardona, V. Casale, T.B. Czarlewski, W. Fokkens, W.J. Hamelmann, E. Hellings, P.W. Jutel, M. Larenas-Linnemann, D. Mullol, J. Papadopoulos, N.G. Toppila-Salmi, S. Werfel, T. Bousquet, J.

Published
2020

44. Aligning the good practice mask with the objectives of the European innovation partnership on active and healthy ageing

Author

Bousquet, J. and Farrell, J. and Onorato, G.L. and Bedbrook, A. and Czarlewski, W. and Micheli, Y. and Arnavielhe, S. and Illario, M. and Ansotegui, I.J. and Anto, J.M. and Bachert, C. and Basagaña, X. and Bédard, A. and Benveniste, S. and Bergmann, K.C. and Bewick, M. and Bindslev-Jensen, C. and Bjermer, L. and Blain, H. and Bosnic-Anticevich, S. and Bosse, I. and Braido, F. and Brussino, L. and Camuzat, T. and Canonica, G.W. and Cardona, V. and Carreiro Martins, P. and Cecchi, L. and Chavannes, N.H. and Chu, D.K. and Correia da Sousa, J. and Costa, D.J. and Costa, E. and Cruz, A.A. and da Silva, J. and Devillier, P. and de Feo, G. and de Vries, G. and Dray, G. and Ebisawa, M. and Erhola, M. and Fauquert, J.L. and Fokkens, W.J. and Fonseca, J. and Fontaine, J.M. and Gemicioğlu, B. and Haahtela, T. and Heffler, E. and Hellings, P.W. and Ivancevich, J.C. and Jassem, E. and Jutel, M. and Kaidashev, I. and Kalayci, O. and Klimek, L. and Kowalski, M.L. and Kull, I. and Kuna, P. and Kvedariene, V. and la Grutta, S. and Laune, D. and Larenas-Linnemann, D. and Ierodiakonou, D. and Le, L.T.T. and Lourenço, O. and Makris, M. and Menditto, E. and Monti, R. and Morais-Almeida, M. and Münter, L. and Muraro, A. and Murray, R. and Maurer, M. and Melén, E. and Mösges, R. and Mullol, J. and Niedoszytko, M. and O'Hehir, R.E. and Okamoto, Y. and Papadopoulos, N.G. and Passalacqua, G. and Patella, V. and Pereira, A.M. and Pfaar, O. and Pham-Thi, N. and Portejoie, F. and Price, D. and Prokopakis, E.P. and Psarros, F. and Raciborski, F. and Regateiro, F. and Reitsma, S. and Roche, N. and Rolland, C. and Ryan, D. and Samolinski, B. and Sastre, J. and Scadding, G.K. and Schmid-Grendelmeier, P. and Schünemann, H.J. and Shamji, M. and Sheikh, A. and Stellato, C. and Suppli-Ulrik, C. and Somekh, D. and Sova, M. and Todo Bom, A. and Tomazic, P.V. and Toppila-Salmi, S. and Triggiani, M. and Tsiligianni, I. and Valero, A. and Valiulis, A. and Valovirta, E. and van Eerd, M. and Vasankari, T. and Ventura, M.T. and Wallace, D. and Waserman, S. and Yorgancioglu, A. and Zidarn, M. and Zuberbier, T., CHU Arnaud de Villeneuve, Montpellier, France, MACVIA-France, Montpellier, France, INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Montigny le Bretonneux, France, Euforea, Brussels, Belgium, Charité - Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany, Department of Dermatology and Allergy, Berlin Institute of Health, Comprehensive Allergy Center, Berlin, Germany, LANUA International Healthcare Consultancy, Belfast, Northern Ireland, United Kingdom, Medical Consulting Czarlewski, Levallois, France, KYomed INNOV, Montpellier, France, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R&D Unit and Department of Public Health), Naples, Italy, Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, Hospital del Mar Research Institute (IMIM), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, Upper Airways Research Laboratory, Department of ENT, Ghent University Hospital, Ghent, Belgium, National Center of Expertise in Cognitive Stimulation (CEN STIMCO), Broca Hospital, Paris, France, Mines ParisTech CRI - PSL Research University, Fontainebleau, France, iQ4U Consultants Ltd, London, United Kingdom, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark, Department of Respiratory Medicine and Allergology, Lund University, Lund, Sweden, Department of Geriatrics, Montpellier University Hospital, Montpellier, France, EA 2991, Euromov, University, Montpellier, France, Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and Sydney Local Health District, Glebe, Australia, La Rochelle, France, University of Genoa, Department of Internal Medicine, DiMI) and IRCCS Ospedale Policlinico San Martino, Genova, Italy, Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino, Mauriziano Hospital, Torino, Italy, Région Occitanie, Montpellier, France, Personalized Medicine Clinic Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano (MI), Italy, Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron and ARADyAL Research Network, Barcelona, Spain, Serviço de Imunoalergologia, Hospital de Dona Estefânia, Centro Hospitalar de Lisboa Central, Lisbon, Portugal, CEDOC-CHRC, Faculdade de Ciências Médicas (FCM), Universidade Nova de Lisboa, Lisbon, Portugal, SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada, Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, Canada, Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal, ICVS/3B's, PT Government Associate Laboratory, Braga/Guimarães, Portugal, Nîmes, France, UCIBIO, REQUIMTE, Faculty of Pharmacy, and Competence Center on Active and Healthy Ageing of University of Porto (AgeUPNetWork), University of Porto, Porto, Portugal, ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Salvador, Brazil, WHO GARD Planning Group, Salvador, Brazil, Allergy Service, University Hospital of Federal University of Santa Catarina (HU-UFSC), Florianópolis, Brazil, UPRES EA220, Pôle des Maladies des Voies Respiratoires, Hôpital Foch, Université Paris-Saclay, Suresnes, France, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Salerno, Italy, Peercode BV, Geldermalsen, Netherlands, IMT Mines Alès, Université Montpellier, France, Clinical Reserch Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, National Insitute for Health and Welfare, Helsinki, Finland, CHU Clermont-Ferrand, Unité d'allergologie de l'enfant, Pôle pédiatrique, Hôpital Estaing, Clermont-Ferrand, France, Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, Medida, Lda, Porto, Portugal, Reims, France, Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istambul, Turkey, Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, Department of Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Department of Allergology, Medical University of Gdańsk, Gdańsk, Poland, Department of Clinical Immunology, Wrocław Medical University, Poland, Ukrainina Medical Stomatological Academy, Poltava, Ukraine, Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey, Center for Rhinology and Allergology, Wiesbaden, Germany, Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, Poland, Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden, Sach's Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Poland, Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Institute of Clinical Medicine, Clinic of Chest diseases and Allergology, Faculty of Medicine, Vilnius, Lithuania, Institute for Research and Biomedical Innovation (IRIB), National Research Council (CNR), Palermo, Italy, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, Department of Social Medicine, Faculty of Medicine, University of Crete, International Primary Care Respiratory Group, Crete, Greece, International Primary Care Respiratory Group IPCRG, Aberdeen, United Kingdom, University of Medicine and Pharmacy, Ho Chi Minh City, Viet Nam, Faculty of Health Sciences and CICS - UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, Allergy Unit 'D Kalogeromitros', 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece, CIRFF, Center of Pharmacoeconomics, University of Naples Federico II, Naples, Italy, Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal, Danish Commitee for Health Education, Copenhagen East, Denmark, Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy, MedScript, Paraparaumu, New Zealand, Optimum Patient Care, Cambridge, United Kingdom, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Germany and CRI-Clinical Research International-Ltd, Hamburg, Germany, Rhinology Unit and Smell Clinic, Department of ENT, Hospital Clínic, Barcelona, Spain, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia, Department of Immunology, Monash University, Melbourne, Australia, Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Division of Infection, Immunity and Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom, Department of Allergy, 2nd Pediatric Clinic, Athens General Children's Hospital 'P&A Kyriakou,', University of Athens, Athens, Greece, Allergy and Respiratory Diseases, Ospedale Policlino San Martino, University of Genoa, Italy, Division of Allergy and Clinical Immunology, Department of Medicine, Agency of Health ASL Salerno, Santa Maria della Speranza Hospital, Salerno, Italy, Allergy Unit, CUF-Porto Hospital and Institute, Porto, Portugal, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Germany, Department of Allergy, Pasteur Institute, Paris, France, Observational and Pragmatic Research Institute, Singapore, Singapore, Department of Otorhinolaryngology, University of Crete, School of Medicine, Heraklion, Greece, Allergy Department, Athens Naval Hospital, Athens, Greece, Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Imunoalergologia, Centro Hospitalar Universitário de Coimbra, Faculty of Medicine, University of Coimbra, Portugal, Pneumologie et Soins Intensifs Respiratoires, Hôpitaux Universitaires Paris, Centre Hôpital Cochin, Paris, France, Association Asthme et Allergie, Paris, France, Allergy and Respiratory Research Group, University of Edinburgh, Edinburgh, United Kingdom, Faculty of Medicine, Autnonous University of Madrid, Spain, Royal National TNE Hospital, University College London, London, United Kingdom, Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zürich, Switzerland, Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Imperial College London, London, United Kingdom, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, Department of Respiratory Medicine, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark, European Health Futures Forum (EHFF), Dromahair, Ireland, Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic, Imunoalergologia, Centro Hospitalar Universitário de Coimbra, Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Department of General ORL, H1NS, Medical University of Graz, Graz, Austria, Vilnius University Faculty of Medicine, Institute of Clinical Medicine, Institute of Health Sciences, Vilnius, Lithuania, European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium, Department of Lung Diseases and Clinical Immunology, University of Turku and Terveystalo Allergy Clinic, Turku, Finland, FILHA, Finnish Lung Association, Helsinki, Finland, University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy, Nova Southeastern University, Fort Lauderdale, FL, United States, Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey, and University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia

Abstract

The reference sites of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) were renewed in 2019. The DG Santé good practice Mobile Airways Sentinel networK was reviewed to meet the objectives of the EIP on AHA. It included 1) Management of care process, 2) Blueprint of digital transformation, 3) EIP on AHA, innovation to market, 4) Community for monitoring and assessment framework, 5) Political, organizational, technological and financial readiness, 6) Contributing to European co-operation and transferability, 7) Delivering evidence of impact against the triple win approach, 8) Contribution to the European Digital Transformation of Health and Care and 9) scale of demonstration and deployment of innovation. © 2020 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:// creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Published
2020

45. Correction to: 'ARIA guideline 2019: treatment of allergic rhinitis in the German health system' (Allergo Journal International, (2019), 28, 7, (255-276), 10.1007/s40629-019-00110-9)

Author

Klimek, L. Bachert, C. Pfaar, O. Becker, S. Bieber, T. Brehler, R. Buhl, R. Casper, I. Chaker, A. Czech, W. Fischer, J. Fuchs, T. Gerstlauer, M. Hörmann, K. Jakob, T. Jung, K. Kopp, M.V. Mahler, V. Merk, H. Mülleneisen, N. Nemat, K. Rabe, U. Ring, J. Saloga, J. Schlenter, W. Schmidt-Weber, C. Seyfarth, H. Sperl, A. Spindler, T. Staubach, P. Strieth, S. Treudler, R. Vogelberg, C. Wallrafen, A. Wehrmann, W. Wrede, H. Zuberbier, T. Bedbrook, A. Canonica, G.W. Cardona, V. Casale, T.B. Czarlewski, W. Fokkens, W.J. Hamelmann, E. Hellings, P.W. Jutel, M. Larenas-Linnemann, D. Mullol, J. Papadopoulos, N.G. Toppila-Salmi, S. Werfel, T. Bousquet, J.

Abstract

Correction to: Allergo J Int 2019 https://doi.org/10.1007/s40629-019-00110-9 Affiliation and disclaimer have been misrepresented and are hereby corrected: Vera Mahler: Affiliation: Med. Faculty, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg, Germany. Disclaimer: The views expressed in this. © 2020, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Published
2020

46. The evolving algorithm of biological selection in severe asthma

Author

Papadopoulos, N.G. Barnes, P. Canonica, G.W. Gaga, M. Heaney, L. Menzies-Gow, A. Kritikos, V. Fitzgerald, M.

Abstract

New therapeutic options for severe asthma have recently emerged, mostly in the form of monoclonal antibodies (“biologicals”) targeting relevant inflammatory pathways. Currently available agents target different aspects of “Type 2” immunity, and their indications often include overlapping patient groups. We present a round-table discussion that took place during the Annual Meeting of the Respiratory Effectiveness Group (REG), on the reasoning behind the use of different add-on medications for severe asthma, and crucially, on selection strategies. The proposed rational is based on current evidence, including real-life studies, as well as on the appreciation of the relevant complexities. Direct head-to-head comparisons of biologicals are lacking; therefore, algorithms for initial choice and potential switch between agents should be based on understanding the key characteristics of different options and the development of a clear plan with predefined targets and shared decision-making, in a structured way. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2020

47. Aligning the good practice mask with the objectives of the European innovation partnership on active and healthy ageing

Author

Bousquet, J., Farrell, J., Illario, M., Onorato, G.L., Bedbrook, A., Czarlewski, W., Micheli, Y., Arnavielhe, S., Ansotegui, I.J., Anto, J.M., Bachert, C., Basagana, X., Bedard, A., Benveniste, S., Bergmann, K.C., Bewick, M., Bindslev-Jensen, C., Bjermer, L., Blain, H., Bosnic-Anticevich, S., Bosse, I., Braido, F., Brussino, L., Camuzat, T., Canonica, G.W., Cardona, V., Martins, P.C., Cecchi, L., Chavannes, N.H., Chu, D.K., Sousa, J.C. da, Costa, D.J., Costa, E., Cruz, A.A., Silva, J. da, Devillier, P., Feo, G. de, Vries, G. de, Dray, G., Ebisawa, M., Erhola, M., Fauquert, J.L., Fokkens, W.J., Fonseca, J., Fontaine, J.M., Gemicioglu, B., Haahtela, T., Heffler, E., Hellings, P.W., Ivancevich, J.C., Jassem, E., Jutel, M., Kaidashev, I., Kalayci, O., Klimek, L., Kowalski, M.L., Kull, I., Kuna, P., Kvedariene, V., Grutta, S. la, Laune, D., Larenas-Linnemann, D., Ierodiakonou, D., L.T.T. le, Lourenco, O., Makris, M., Menditto, E., Monti, R., Morais-Almeida, M., Munter, L., Muraro, A., Murray, R., Maurer, M., Melen, E., Mosges, R., Mullol, J., Niedoszytko, M., O'Hehir, R.E., Okamoto, Y., Papadopoulos, N.G., Passalacqua, G., Patella, V., Pereira, A.M., Pfaar, O., Pham-Thi, N., Portejoie, F., Price, D., Prokopakis, E.P., Psarros, F., Raciborski, F., Regateiro, F., Reitsma, S., Roche, N., Rolland, C., Ryan, D., Samolinski, B., Sastre, J., Scadding, G.K., Schmid-Grendelmeier, P., Schunemann, H.J., Shamji, M., Sheikh, A., Stellato, C., Suppli-Ulrik, C., Somekh, D., Sova, M., Bom, A.T., Tomazic, P.V., Toppila-Salmi, S., Triggiani, M., Tsiligianni, I., Valero, A., Valiulis, A., Valovirta, E., Eerd, M. van, Vasankari, T., Ventura, M.T., Wallace, D., Waserman, S., Yorgancioglu, A., Zidarn, M., Zuberbier, T., ARIA-MASK Study Grp, Bousquet, J., Farrell, J., Onorato, G. L., Bedbrook, A., Czarlewski, W., Micheli, Y., Arnavielhe, S., Illario, M., Ansotegui, I. J., Anto, J. M., Bachert, C., Basagana, X., Bedard, A., Benveniste, S., Bergmann, K. C., Bewick, M., Bindslev-Jensen, C., Bjermer, L., Blain, H., Bosnic-Anticevich, S., Bosse, I., Braido, F., Brussino, L., Camuzat, T., Canonica, G. W., Cardona, V., Carreiro Martins, P., Cecchi, L., Chavannes, N. H., Chu, D. K., Correia da Sousa, J., Costa, D. J., Costa, E., Cruz, A. A., da Silva, J., Devillier, P., de Feo, G., de Vries, G., Dray, G., Ebisawa, M., Erhola, M., Fauquert, J. L., Fokkens, W. J., Fonseca, J., Fontaine, J. M., Gemicioglu, B., Haahtela, T., Heffler, E., Hellings, P. W., Ivancevich, J. C., Jassem, E., Jutel, M., Kaidashev, I., Kalayci, O., Klimek, L., Kowalski, M. L., Kull, I., Kuna, P., Kvedariene, V., la Grutta, S., Laune, D., Larenas-Linnemann, D., Ierodiakonou, D., Le, L. T. T., Lourenco, O., Makris, M., Menditto, E., Monti, R., Morais-Almeida, M., Munter, L., Muraro, A., Murray, R., Maurer, M., Melen, E., Mosges, R., Mullol, J., Niedoszytko, M., O'Hehir, R. E., Okamoto, Y., Papadopoulos, N. G., Passalacqua, G., Patella, V., Pereira, A. M., Pfaar, O., Pham-Thi, N., Portejoie, F., Price, D., Prokopakis, E. P., Psarros, F., Raciborski, F., Regateiro, F., Reitsma, S., Roche, N., Rolland, C., Ryan, D., Samolinski, B., Sastre, J., Scadding, G. K., Schmid-Grendelmeier, P., Schunemann, H. J., Shamji, M., Sheikh, A., Stellato, C., Suppli-Ulrik, C., Somekh, D., Sova, M., Todo Bom, A., Tomazic, P. V., Toppila-Salmi, S., Triggiani, M., Tsiligianni, I., Valero, A., Valiulis, A., Valovirta, E., van Eerd, M., Vasankari, T., Ventura, M. T., Wallace, D., Waserman, S., Yorgancioglu, A., Zidarn, M., Zuberbier, T., Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Ghent University Hospital, Department of Dermatology and Allergy Center, Odense University Hospital, The University of Sydney, Informatique, Image, Intelligence Artificielle (I3A), Laboratoire de Génie Informatique et d'Ingénierie de Production (LGI2P), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-IMT - MINES ALES (IMT - MINES ALES), and Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)

Subjects
Pulmonary and Respiratory Medicine, Process management, Allergy, IMPACT, Immunology, Mobile application, Review, health, Clinical decision support system, GLOBAL ALLIANCE, Asthma, Health, Healthy aging, Mobile applications, Rhinitis, Financial management, 03 medical and health sciences, [SPI]Engineering Sciences [physics], 0302 clinical medicine, Blueprint, QUALITY-OF-LIFE, HDE ALER, Health care, Medicine and Health Sciences, Immunology and Allergy, Medicine, TECHNOLOGY, 030223 otorhinolaryngology, Total quality management, Science & Technology, ARIA, business.industry, Digital transformation, GENERATION CARE PATHWAYS, ALLERGIC RHINITIS, CHRONIC RESPIRATORY-DISEASES, 030228 respiratory system, General partnership, GA(2)LEN, business, Life Sciences & Biomedicine, ASTHMA MULTIMORBIDITY, Health care quality
Abstract

The reference sites of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) were renewed in 2019. The DG Santé good practice Mobile Airways Sentinel networK was reviewed to meet the objectives of the EIP on AHA. It included 1) Management of care process, 2) Blueprint of digital transformation, 3) EIP on AHA, innovation to market, 4) Community for monitoring and assessment framework, 5) Political, organizational, technological and financial readiness, 6) Contributing to European co-operation and transferability, 7) Delivering evidence of impact against the triple win approach, 8) Contribution to the European Digital Transformation of Health and Care and 9) scale of demonstration and deployment of innovation. ispartof: ALLERGY ASTHMA & IMMUNOLOGY RESEARCH vol:12 issue:2 pages:238-258 ispartof: location:Korea (South) status: published

Published
2020

48. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

Author

Agache, I. Beltran, J. Akdis, C. Akdis, M. Canelo-Aybar, C. Canonica, G.W. Casale, T. Chivato, T. Corren, J. Del Giacco, S. Eiwegger, T. Firinu, D. Gern, J.E. Hamelmann, E. Hanania, N. Mäkelä, M. Hernández-Martín, I. Nair, P. O'Mahony, L. Papadopoulos, N.G. Papi, A. Park, H.-S. Pérez de Llano, L. Posso, M. Rocha, C. Quirce, S. Sastre, J. Shamji, M. Song, Y. Steiner, C. Schwarze, J. Alonso-Coello, P. Palomares, O. Jutel, M.

Abstract

Five biologicals have been approved for severe eosinophilic asthma, a well-recognized phenotype. Systematic reviews (SR) evaluated the efficacy and safety of benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab (alphabetical order) compared to standard of care for severe eosinophilic asthma. PubMed, Embase and Cochrane Library were searched to identify RCTs and health economic evaluations, published in English. Critical and important asthma-related outcomes were evaluated for each of the biologicals. The risk of bias and the certainty of the evidence were assessed using GRADE. 19 RCTs (three RCTs for benralizumab, three RCTs for dupilumab, three RCTs for mepolizumab, five RCTs for omalizumab and five RCTs for reslizumab), including subjects 12 to 75 years old (except for omalizumab including also subjects 6-11 years old), ranging from 12 to 56 weeks were evaluated. All biologicals reduce exacerbation rates with high certainty of evidence: benralizumab incidence rate ratio (IRR) 0.53 (95% CI 0.39 to 0.72), dupilumab (IRR) 0.43 (95% CI 0.32 to 0.59), mepolizumab IRR 0.49 (95% CI 0.38 to 0.66), omalizumab (IRR) 0.56 (95% CI 0.40 to 0.77) and reslizumab (IRR) 0.46 (95% CI 0.37 to 0.58). Benralizumab, dupilumab and mepolizumab reduce the daily dose of oral corticosteroids (OCS) with high certainty of evidence. All evaluated biologicals probably improve asthma control, QoL and FEV1, without reaching the minimal important difference (moderate certainty). Benralizumab, mepolizumab and reslizumab slightly increase drug-related adverse events (AE) and drug-related serious AE (low to very low certainty of evidence). The incremental cost-effectiveness ratio per quality-adjusted life year value is above the willingness to pay threshold for all biologicals (moderate certainty). Potential savings are driven by decrease in hospitalizations, emergency and primary care visits. There is high certainty that all approved biologicals reduce the rate of severe asthma exacerbations and for benralizumab, dupilumab and mepolizumab for reducing OCS. There is moderate certainty for improving asthma control, QoL, FEV1. More data on long-term safety are needed together with more efficacy data in the paediatric population. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2020

49. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma

Author

Agache, I. Song, Y. Rocha, C. Beltran, J. Posso, M. Steiner, C. Alonso-Coello, P. Akdis, C. Akdis, M. Canonica, G.W. Casale, T. Chivato, T. Corren, J. del Giacco, S. Eiwegger, T. Firinu, D. Gern, J.E. Hamelmann, E. Hanania, N. Mäkelä, M. Martín, I.H. Nair, P. O'Mahony, L. Papadopoulos, N.G. Papi, A. Park, H.-S. Pérez de Llano, L. Quirce, S. Sastre, J. Shamji, M. Schwarze, J. Canelo-Aybar, C. Palomares, O. Jutel, M.

Abstract

Dupilumab, a fully human monoclonal antibody against interleukin-4 receptor α, is approved as add-on maintenance treatment for inadequately controlled type 2 severe asthma. This systematic review evaluated the efficacy, safety and economic impact of dupilumab compared to standard of care for uncontrolled severe asthma. PubMed, EMBASE and Cochrane Library were searched for RCTs and health economic evaluations. Critical and important asthma-related outcomes were evaluated. The risk of bias and the certainty of the evidence were assessed using GRADE. Three RCTs including 2735 subjects >12 years old and 24-52 weeks of follow-up were included. Dupilumab reduced with high certainty severe asthma exacerbations (Incidence rate ratio 0.51; 95% CI 0.45-0.59) and the percentage use of oral corticosteroid use (mean difference (MD) −28.2 mg/d; 95% CI −40.7 to −15.7). Asthma control (ACQ-5), quality of life (AQLQ) and rescue medication use [puffs/d] improved, without reaching the minimal important clinical difference: ACQ-5 MD −0.28 (95% CI −0.39 to −0.17); AQLQ MD +0.28 (95% CI 0.20-0.37); and rescue medication MD −0.35 (95% CI −0.73 to +0.02). FEV1 increased (MD +0.15; 95% CI +0.11 to +0.18) (moderate certainty). There was an increased rate of dupilumab-related adverse events (AEs) (moderate certainty) and of drug-related serious AEs (low certainty). The incremental cost-effectiveness ratio of dupilumab versus standard therapy was 464 000$/QALY (moderate certainty). More data on long-term safety are needed both for children and for adults, together with more efficacy data in the paediatric population. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2020

50. International severe asthma registry (ISAR): Protocol for a global registry

Author

Fitzgerald, J.M. Tran, T.N. Alacqua, M. Altraja, A. Backer, V. Bjermer, L. Bjornsdottir, U. Bourdin, A. Brusselle, G. Bulathsinhala, L. Busby, J. Canonica, G.W. Carter, V. Chaudhry, I. Cho, Y.S. Christoff, G. Cosio, B.G. Costello, R.W. Eleangovan, N. Gibson, P.G. Heaney, L.G. Heffler, E. Hew, M. Hosseini, N. Iwanaga, T. Jackson, D.J. Jones, R. Koh, M.S. Le, T. Lehtimäki, L. Ludviksdottir, D. Maitland-Van Der Zee, A.H. Menzies-Gow, A. Murray, R.B. Papadopoulos, N.G. Perez-De-Llano, L. Peters, M. Pfeffer, P.E. Popov, T.A. Porsbjerg, C.M. Price, C.A. Rhee, C.K. Sadatsafavi, M. Tohda, Y. Wang, E. Wechsler, M.E. Zangrilli, J. Price, D.B.

Abstract

Background: Severe asthma exerts a disproportionately heavy burden on patients and health care. Due to the heterogeneity of the severe asthma population, many patients need to be evaluated to understand the clinical features and outcomes of severe asthma in order to facilitate personalised and targeted care. The International Severe Asthma Registry (ISAR) is a multi-country registry project initiated to aid in this endeavour. Methods: ISAR is a multi-disciplinary initiative benefitting from the combined experience of the ISAR Steering Committee (ISC; comprising 47 clinicians and researchers across 29 countries, who have a special interest and/or experience in severe asthma management or establishment and maintenance of severe asthma registries) in collaboration with scientists and experts in database management and communication. Patients (=18 years old) receiving treatment according to the 2018 definitions of the Global Initiative for Asthma (GINA) Step 5 or uncontrolled on GINA Step 4 treatment will be included. Data will be collected on a core set of 95 variables identified using the Delphi method. Participating registries will agree to provide access to and share standardised anonymous patient-level data with ISAR. ISAR is a registered data source on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ISAR's collaborators include Optimum Patient Care, the Respiratory Effectiveness Group (REG) and AstraZeneca. ISAR is overseen by the ISC, REG, the Anonymised Data Ethics and Protocol Transparency Committee and the ISAR operational committee, ensuring the conduct of ethical, clinically relevant research that brings value to all key stakeholders. Conclusions: ISAR aims to offer a rich source of real-life data for scientific research to understand and improve disease burden, treatment patterns and patient outcomes in severe asthma. Furthermore, the registry will provide an international platform for research collaboration in respiratory medicine, with the overarching aim of improving primary and secondary care of adults with severe asthma globally. © 2020 The Author(s).

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results